Ontogeny of Recognition Specificity and Functionality for the Broadly Neutralizing Anti-HIV Antibody 4E10

PLoS Pathogens

Volumn 10, Issue 9, 2014, Pages

  Finton, Kathryn A K ^a   Friend, Della ^a   Jaffe, James ^a   Gewe, Mesfin ^a   Holmes, Margaret A ^a   Larman, H Benjamin ^b   Stuart, Andrew ^c   Larimore, Kevin ^d   Greenberg, Philip D ^a,d   Elledge, Stephen J ^b   Stamatatos, Leonidas ^c,e   Strong, Roland K ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c SEATTLE BIOMEDICAL RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; MONOCLONAL ANTIBODY 4E10; NEUTRALIZING ANTIBODY; 4E10 MONOCLONAL ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; MONOCLONAL ANTIBODY;

AFFINITY CHROMATOGRAPHY; ANTIBODY SPECIFICITY; ARTICLE; CRYSTAL STRUCTURE; CRYSTALLIZATION; CRYSTALLOGRAPHY; GEL PERMEATION CHROMATOGRAPHY; GENE MUTATION; HYDROGEN BOND; HYDROPHOBICITY; IMMUNIZATION; KINETICS; ONTOGENY; SPECTROSCOPY; VACCINATION; VALIDATION PROCESS; AMINO ACID SEQUENCE; CHEMISTRY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; METABOLISM; MOLECULAR GENETICS; SEQUENCE HOMOLOGY; SERODIAGNOSIS; SURFACE PLASMON RESONANCE; VIROLOGY; X RAY CRYSTALLOGRAPHY;

AMINO ACID SEQUENCE; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; CRYSTALLOGRAPHY, X-RAY; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; SEQUENCE HOMOLOGY, AMINO ACID; SURFACE PLASMON RESONANCE;

EID: 84907584631     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1004403     Document Type: Article

References (80)

1. Stephenson KE, Barouch DH, (2013) A global approach to HIV-1 vaccine development. Immunol Rev 254: 295–304.
2. Haynes BF, McElrath MJ, (2013) Progress in HIV-1 vaccine development. Curr Opin HIV AIDS 8: 326–332.
3. Bonsignori M, Alam SM, Liao HX, Verkoczy L, Tomaras GD, et al. (2012) HIV-1 antibodies from infection and vaccination: insights for guiding vaccine design. Trends Microbiol 20: 532–539.
4. Klein F, Mouquet H, Dosenovic P, Scheid JF, Scharf L, et al. (2013) Antibodies in HIV-1 vaccine development and therapy. Science 341: 1199–1204.
5. Stamatatos L, (2012) HIV vaccine design: the neutralizing antibody conundrum. Curr Opin Immunol 24: 316–323.
6. Burton DR, (2002) Antibodies, viruses and vaccines. Nat Rev Immunol 2: 706–713.
7. Lang J, Jackson M, Teyton L, Brunmark A, Kane K, et al. (1996) B cells are exquisitely sensitive to central tolerance and receptor editing induced by ultralow affinity, membrane-bound antigen. J Exp Med 184: 1685–1697.
8. Qi H, Egen JG, Huang AY, Germain RN, (2006) Extrafollicular activation of lymph node B cells by antigen-bearing dendritic cells. Science 312: 1672–1676.
9. Batista FD, Neuberger MS, (1998) Affinity dependence of the B cell response to antigen: a threshold, a ceiling, and the importance of off-rate. Immunity 8: 751–759.
10. Kim M, Sun ZY, Rand KD, Shi X, Song L, et al. (2011) Antibody mechanics on a membrane-bound HIV segment essential for GP41-targeted viral neutralization. Nat Struct Mol Biol 18: 1235–1243.
11. Julien JP, Huarte N, Maeso R, Taneva SG, Cunningham A, et al. (2010) Ablation of the complementarity-determining region H3 apex of the anti-HIV-1 broadly neutralizing antibody 2F5 abrogates neutralizing capacity without affecting core epitope binding. J Virol 84: 4136–4147.
12. Cardoso RM, Zwick MB, Stanfield RL, Kunert R, Binley JM, et al. (2005) Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41. Immunity 22: 163–173.
13. Zwick MB, Labrijn AF, Wang M, Spenlehauer C, Saphire EO, et al. (2001) Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J Virol 75: 10892–10905.
14. Binley JM, Wrin T, Korber B, Zwick MB, Wang M, et al. (2004) Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J Virol 78: 13232–13252.
15. Correia BE, Ban YE, Holmes MA, Xu H, Ellingson K, et al. (2010) Computational design of epitope-scaffolds allows induction of antibodies specific for a poorly immunogenic HIV vaccine epitope. Structure 18: 1116–1126.
16. Larimore K, McCormick MW, Robins HS, Greenberg PD, (2012) Shaping of Human Germline IgH Repertoires Revealed by Deep Sequencing. J Immunol 189 (6) 3221–30.
17. Finton KA, Larimore K, Larman HB, Friend D, Correnti C, et al. (2013) Autoreactivity and exceptional CDR plasticity (but not unusual polyspecificity) hinder elicitation of the anti-HIV antibody 4E10. PLoS Pathog 9: e1003639.
18. Xu H, Song L, Kim M, Holmes MA, Kraft Z, et al. (2010) Interactions between lipids and human anti-HIV antibody 4E10 can be reduced without ablating neutralizing activity. J Virol 84: 1076–1088.
19. Doyle-Cooper C, Hudson KE, Cooper AB, Ota T, Skog P, et al. (2013) Immune tolerance negatively regulates B cells in knock-in mice expressing broadly neutralizing HIV antibody 4E10. J Immunol 191: 3186–3191.
20. Chen Y, Zhang J, Hwang KK, Bouton-Verville H, Xia SM, et al. (2013) Common tolerance mechanisms, but distinct cross-reactivities associated with gp41 and lipids, limit production of HIV-1 broad neutralizing antibodies 2F5 and 4E10. J Immunol 191: 1260–1275.
21. Ruprecht CR, Krarup A, Reynell L, Mann AM, Brandenberg OF, et al. (2011) MPER-specific antibodies induce gp120 shedding and irreversibly neutralize HIV-1. J Exp Med 208: 439–454.
22. Alam SM, Morelli M, Dennison SM, Liao HX, Zhang R, et al. (2009) Role of HIV membrane in neutralization by two broadly neutralizing antibodies. Proc Natl Acad Sci U S A 106: 20234–20239.
23. Amzel LM, Poljak RJ, (1979) Three-dimensional structure of immunoglobulins. Ann Rev Biochem 48: 961–997.
24. Wu TT, Kabat EA, (1970) An analysis of the sequences of the variable regions of Bence Jones proteins and myeloma light chains and their implications for antibody complementarity. J Exp Med 132: 211–250.
25. Breden F, Lepik C, Longo NS, Montero M, Lipsky PE, et al. (2011) Comparison of antibody repertoires produced by HIV-1 infection, other chronic and acute infections, and systemic autoimmune disease. PLoS One 6: e16857.
26. Xiao X, Chen W, Feng Y, Zhu Z, Prabakaran P, et al. (2009) Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: implications for evasion of immune responses and design of vaccine immunogens. Biochem Biophys Res Commun 390: 404–409.
27. Scheid JF, Mouquet H, Ueberheide B, Diskin R, Klein F, et al. (2011) Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 333: 1633–1637.
28. Zhou T, Georgiev I, Wu X, Yang ZY, Dai K, et al. (2010) Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 329: 811–817.
29. McGuire AT, Hoot S, Dreyer AM, Lippy A, Stuart A, et al. (2013) Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies. J Exp Med 210: 655–663.
30. Bates JT, Keefer CJ, Utley TJ, Correia BE, Schief WR, et al. (2013) Reversion of somatic mutations of the respiratory syncytial virus-specific human monoclonal antibody Fab19 reveal a direct relationship between association rate and neutralizing potency. J Immunol 190: 3732–3739.
31. Wu X, Zhou T, Zhu J, Zhang B, Georgiev I, et al. (2011) Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science 333: 1593–1602.
32. Johnson G, Wu TT, (2000) Kabat database and its applications: 30 years after the first variability plot. Nucleic Acids Res 28: 214–218.
33. Johnson G, Wu TT, (1998) Preferred CDRH3 lengths for antibodies with defined specificities. Int Immunol 10: 1801–1805.
34. Ma BJ, Alam SM, Go EP, Lu X, Desaire H, et al. (2011) Envelope deglycosylation enhances antigenicity of HIV-1 gp41 epitopes for both broad neutralizing antibodies and their unmutated ancestor antibodies. PLoS Pathog 7: e1002200.
35. Foote J, Eisen HN, (1995) Kinetic and affinity limits on antibodies produced during immune responses. Proc Natl Acad Sci U S A 92: 1254–1256.
36. Thomson CA, Bryson S, McLean GR, Creagh AL, Pai EF, et al. (2008) Germline V-genes sculpt the binding site of a family of antibodies neutralizing human cytomegalovirus. EMBO J 27: 2592–2602.
37. Scharf L, West AP, JrGao H, Lee T, Scheid JF, et al. (2013) Structural basis for HIV-1 gp120 recognition by a germ-line version of a broadly neutralizing antibody. Proc Natl Acad Sci U S A 110: 6049–6054.
38. Wang F, Sen S, Zhang Y, Ahmad I, Zhu X, et al. (2013) Somatic hypermutation maintains antibody thermodynamic stability during affinity maturation. Proc Natl Acad Sci U S A 110: 4261–4266.
39. Lingwood D, McTamney PM, Yassine HM, Whittle JR, Guo X, et al. (2012) Structural and genetic basis for development of broadly neutralizing influenza antibodies. Nature 489: 566–570.
40. Schmidt AG, Xu H, Khan AR, O'Donnell T, Khurana S, et al. (2013) Preconfiguration of the antigen-binding site during affinity maturation of a broadly neutralizing influenza virus antibody. Proc Natl Acad Sci U S A 110: 264–269.
41. Wedemayer GJ, Patten PA, Wang LH, Schultz PG, Stevens RC, (1997) Structural insights into the evolution of an antibody combining site. Science 276: 1665–1669.
42. Manivel V, Sahoo NC, Salunke DM, Rao KV, (2000) Maturation of an antibody response is governed by modulations in flexibility of the antigen-combining site. Immunity 13: 611–620.
43. Babor M, Kortemme T, (2009) Multi-constraint computational design suggests that native sequences of germline antibody H3 loops are nearly optimal for conformational flexibility. Proteins 75: 846–858.
44. Sethi DK, Agarwal A, Manivel V, Rao KV, Salunke DM, (2006) Differential epitope positioning within the germline antibody paratope enhances promiscuity in the primary immune response. Immunity 24: 429–438.
45. Yin J, Beuscher AEt, Andryski SE, Stevens RC, Schultz PG, (2003) Structural plasticity and the evolution of antibody affinity and specificity. J Mol Biol 330: 651–656.
46. Yin J, Mundorff EC, Yang PL, Wendt KU, Hanway D, et al. (2001) A comparative analysis of the immunological evolution of antibody 28B4. Biochemistry 40: 10764–10773.
47. Nguyen HP, Seto NO, MacKenzie CR, Brade L, Kosma P, et al. (2003) Germline antibody recognition of distinct carbohydrate epitopes. Nat Struct Biol 10: 1019–1025.
48. Pauling L, (1940) Theory of the Structure and Process of Formation of Antibodies. J Am Chem Soc 62: 2643–2657.
49. Changeux JP, Edelstein S, (2011) Conformational selection or induced fit? 50 years of debate resolved. F1000 Biol Rep 3: 19.
50. Larman HB, Zhao Z, Laserson U, Li MZ, Ciccia A, et al. (2011) Autoantigen discovery with a synthetic human peptidome. Nat Biotechnol 29: 535–541.
51. Blish CA, Nedellec R, Mandaliya K, Mosier DE, Overbaugh J, (2007) HIV-1 subtype A envelope variants from early in infection have variable sensitivity to neutralization and to inhibitors of viral entry. AIDS 21: 693–702.
52. Cheng-Mayer C, Levy JA, (1988) Distinct biological and serological properties of human immunodeficiency viruses from the brain. Ann Neurol 23 Suppl: S58–61.
53. Derby NR, Kraft Z, Kan E, Crooks ET, Barnett SW, et al. (2006) Antibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heterologous HIV-1 infection. J Virol 80: 8745–8762.
54. Davenport TM, Friend D, Ellingson K, Xu H, Caldwell Z, et al. (2011) Binding interactions between soluble HIV envelope glycoproteins and quaternary-structure-specific MAbs PG9 and PG16. J Virol 85: 7095–7107.
55. Correia BE, Ban YE, Friend DJ, Ellingson K, Xu H, et al. (2011) Computational protein design using flexible backbone remodeling and resurfacing: case studies in structure-based antigen design. J Mol Biol 405: 284–297.
56. Lawrence M, Colman PM, (1993) Shape complementarity at protein/protein interfaces. J Mol Biol 234: 946–950.
57. Burton DR, (2010) Scaffolding to build a rational vaccine design strategy. Proc Natl Acad Sci U S A 107: 17859–17860.
58. Graves SS, Stone DM, Loretz C, Peterson LJ, Lesnikova M, et al. (2011) Antagonistic and agonistic anti-canine CD28 monoclonal antibodies: tools for allogeneic transplantation. Transplantation 91: 833–840.
59. Gorny MK, Conley AJ, Karwowska S, Buchbinder A, Xu JY, et al. (1992) Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody. J Virol 66: 7538–7542.
60. Roben P, Moore JP, Thali M, Sodroski J, Barbas CF, 3rdet al. (1994) Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1. J Virol 68: 4821–4828.
61. Klein F, Diskin R, Scheid JF, Gaebler C, Mouquet H, et al. (2013) Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization. Cell 153: 126–138.
62. Lavoie TB, Mohan S, Lipschultz CA, Grivel JC, Li Y, et al. (1999) Structural differences among monoclonal antibodies with distinct fine specificities and kinetic properties. Mol Immunol 36: 1189–1205.
63. Souto-Carneiro MM, Longo NS, Russ DE, Sun HW, Lipsky PE, (2004) Characterization of the human Ig heavy chain antigen binding complementarity determining region 3 using a newly developed software algorithm, JOINSOLVER. J Immunol 172: 6790–6802.
64. Brochet X, Lefranc MP, Giudicelli V, (2008) IMGT/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis. Nucleic Acids Res 36: W503–508.
65. Giudicelli V, Chaume D, Lefranc MP, (2004) IMGT/V-QUEST, an integrated software program for immunoglobulin and T cell receptor V-J and V-D-J rearrangement analysis. Nucleic Acids Res 32: W435–440.
66. Wang X, Wu D, Zheng S, Sun J, Tao L, et al. (2008) Ab-origin: an enhanced tool to identify the sourcing gene segments in germline for rearranged antibodies. BMC Bioinformatics 9 Suppl 12: S20.
67. Volpe JM, Cowell LG, Kepler TB, (2006) SoDA: implementation of a 3D alignment algorithm for inference of antigen receptor recombinations. Bioinformatics 22: 438–444.
68. Gaeta BA, Malming HR, Jackson KJ, Bain ME, Wilson P, et al. (2007) iHMMune-align: hidden Markov model-based alignment and identification of germline genes in rearranged immunoglobulin gene sequences. Bioinformatics 23: 1580–1587.
69. Myszka DG, (1999) Improving biosensor analysis. J Mol Recognit 12: 279–284.
70. Otwinowski Z, Minor W (1997) Processing of X-ray Diffraction Data Collected in Oscillation Mode. In: Jr CWC, Sweet RM, editors. Meth Enzymol. NY: Academic Press. pp. 307–326.
71. Pflugrath JW, (1999) The finer things in X-ray diffraction data collection. Acta Crystallogr D Biol Crystallogr 55: 1718–1725.
72. McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, et al. (2007) Phaser crystallographic software. Journal of Applied Crystallography 40: 658–674.
73. Collaborative Computational Project N (1994) The CCP4 Suite: Programs for Protein Crystallography. Acta Cryst D50: 760–763.
74. Potterton E, Briggs P, Turkenburg M, Dodson E, (2003) A graphical user interface to the CCP4 program suite. Acta Crystallogr D Biol Crystallogr 59: 1131–1137.
75. Emsley P, Cowtan K, (2004) Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60: 2126–2132.
76. Murshudov GN, Vagin AA, Dodson EJ, (1997) Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr 53: 240–255.
77. Laskowski RA, MacArthur MW, Moss DS, Thornton JM, (1993) PROCHECK: a program to check the stereochemical quality of protein structures. Journal of Applied Crystallography 26: 283–291.
78. Davis IW, Leaver-Fay A, Chen VB, Block JN, Kapral GJ, et al. (2007) MolProbity: all-atom contacts and structure validation for proteins and nucleic acids. Nucleic Acids Res 35: W375–383.
79. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, et al. (2000) The Protein Data Bank. Nucleic Acids Research 28: 235–242.
80. Pettit FK, Bare E, Tsai A, Bowie JU, (2007) HotPatch: a statistical approach to finding biologically relevant features on protein surfaces. J Mol Biol 369: 863–879.